Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndromes (MDS). Most patients with MDS are older than 60 years and age-associated morbidities limit the patients’ options for curative transplant therapy. Since the development of co...

Descripción completa

Detalles Bibliográficos
Autores principales: Field, Teresa, Anasetti., Claudio
Formato: Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2010
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033135/
https://www.ncbi.nlm.nih.gov/pubmed/21415970
http://dx.doi.org/10.4084/MJHID.2010.019
_version_ 1782197545538158592
author Field, Teresa
Anasetti., Claudio
author_facet Field, Teresa
Anasetti., Claudio
author_sort Field, Teresa
collection PubMed
description Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndromes (MDS). Most patients with MDS are older than 60 years and age-associated morbidities limit the patients’ options for curative transplant therapy. Since the development of conditioning regimens with reduced toxicity, the age limitations for HCT have waned for those patients with good performance status. This review will discuss the role of HCT for MDS based on prognostic features, the optimal timing of HCT, and outcomes based on patient age.
format Text
id pubmed-3033135
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-30331352011-03-17 Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome Field, Teresa Anasetti., Claudio Mediterr J Hematol Infect Dis Review Articles Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndromes (MDS). Most patients with MDS are older than 60 years and age-associated morbidities limit the patients’ options for curative transplant therapy. Since the development of conditioning regimens with reduced toxicity, the age limitations for HCT have waned for those patients with good performance status. This review will discuss the role of HCT for MDS based on prognostic features, the optimal timing of HCT, and outcomes based on patient age. Università Cattolica del Sacro Cuore 2010-08-05 /pmc/articles/PMC3033135/ /pubmed/21415970 http://dx.doi.org/10.4084/MJHID.2010.019 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
spellingShingle Review Articles
Field, Teresa
Anasetti., Claudio
Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title_full Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title_fullStr Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title_full_unstemmed Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title_short Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
title_sort role and timing of hematopoietic cell transplantation for myelodysplastic syndrome
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033135/
https://www.ncbi.nlm.nih.gov/pubmed/21415970
http://dx.doi.org/10.4084/MJHID.2010.019
work_keys_str_mv AT fieldteresa roleandtimingofhematopoieticcelltransplantationformyelodysplasticsyndrome
AT anasetticlaudio roleandtimingofhematopoieticcelltransplantationformyelodysplasticsyndrome

Ejemplares similares